Abstract
Polymerase Epsilon (POLE)-mutant endometrial cancer accounts for 7%-12% of endometrial cancer molecular types, and most of these patients are early-stage endometrioid carcinoma. Although POLE-mutant endometrial cancer has some unfavorable pathological features such as being poorly differentiated, the overall prognosis is good, and postoperative adjuvant treatment may be considered for de-escalation. POLE-mutant endometrial cancer is relatively less sensitive to postoperative adjuvant chemotherapy or radiotherapy, but because of its ultra-high tumor mutation load, recurrent or advanced patients are expected to benefit from programmed cell death receptor 1 (PCDR1) blockade therapy. This review will discuss the clinical features of POLE-mutated endometrial carcinoma and the progress made in the detection of POLE gene mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
